viewTodos Medical Ltd.

Todos Medical says it expects COVID-19 testing sales to drive business in the near term

Todos Medical CEO Gerald Commissiong believes the company has positioned itself as a ‘one stop shop’ for all things COVID testing related

Todos Medical Ltd. -
Todos Medical said it will be releasing data from its ongoing COVID-19 studies in Israel in the coming weeks

Todos Medical Ltd (OTCQB:TOMDF) CEO Gerald Commissiong provided an update to shareholders on Friday, saying it is “squarely focused” on COVID-19 for the immediate term and expects revenues generated from sales of its COVID-19 testing solutions to be a near-term driver of business.  

"We expect the revenues we generate from sales of COVID-19 testing solutions to drive the business in the near-term and position the company to capitalize on the very significant programs we have in cancer and Alzheimer’s diagnostics," Commissiong said in a letter to shareholders.  

The Todos Medical CEO noted that its immediate attention is on providing solutions to address testing, tracing and immune support in response to the COVID-19 pandemic, positioning it as a ‘one stop shop’ for all things COVID testing related. 

READ:Todos Medical clocks up $867,000 in sales for October

Todos Medical said it received its first payments from a $47.5 million contract with a Wisconsin-based client on October 9, 2020, adding that existing contracts have the potential to deliver over $60 million in revenue by the end of the second-quarter of 2021.

"Todos has optimized a workflow with Tecan liquid handlers currently being implemented at our Wisconsin client that will allow their lab to reach at least 20,000 diagnostic tests per day and with pooling strategies being deployed for screening purposes, this client is expected to reach capacity to conduct over 100,000 tests per day," said Commissiong. 

"As they scale, we expect our sales to scale with them and we will be working very closely with them to overcome any barriers they have to meeting their full potential." 

Commissiong said the company has also secured rights to several COVID-19 tests that are currently awaiting emergency use authorization (EUA) approval from the Food and Drug Administration (FDA), including point-of-care Polymerase Chain Reaction (PCR) tests that will compete with the Abbott ID Now and Cepheid point of care molecular tests.  

The company also expects to enter into an agreement to secure distribution rights to lab-based tests to more comprehensively evaluate COVID-19 immune-status. Todos Medical intends to first bring to market a lab-based test that will monitor PCR positive COVID-19 infected patients for active viral load, and thereafter a point-of-care test that can be used to replace antigen testing for screening and surveillance purposes. It said it will be releasing data from its ongoing studies in Israel in the coming weeks.

He added, though, that Todos Medical has decided to push back its Nasdaq up-listing until the first half of 2021, after “we have demonstrated several more months of growing sales and commercial execution,” focusing instead on creating value for its shareholders.

On Thursday, Todos Medical reported revenue of $867,000 in October 2020, a 147% month-over-month increase that was driven by extraction reagents sales. It said current weekly orders for extraction reagents have increased to over 40,000 units per week for the company’s legacy clients.

Todos is helping its five largest contracted clients to complete qPCR kits validations and expects those qPCR kit sales to start flowing from the end of November 2020. The company will soon have the capacity to run more than 350,000 tests per week.

Contact Sean at [email protected]

Quick facts: Todos Medical Ltd.

Price: 0.066 USD

Market: OTCQB
Market Cap: $13.32 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Todos Medical Ltd. named herein, including the promotion by the Company of Todos Medical Ltd. in any Content on the Site, the Company receives...


Todos Medical forms distribution agreement with coronavirus immunity-focused...

Todos Medical Ltd (OTCQB:TOMDF) CEO Gerald Commissiong tells it has signed an agreement with Aditx Therapeutics Inc (NASDAQ:ADTX), through which it has secured the rights to distribute Aditx’s immune-related AditxtScore COVID-19 scoring system, with planned availability in January...

on 12/14/2020

3 min read